June 03,2009- Genta Incorporated (OTCBB: GNTA | Quote | Chart | News | PowerRating) announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, in a chemotherapy program for patients with advanced melanoma. The data were featured this week in a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL.
About ESR:
Emerging Stock Report is a leading provider of independent investment research in North America our services include, research analysis on the small cap markets, real time news and financial data, market commentary and the ESR newsletter .Emerging Stock Report's staff of small cap investment professionals is dedicated to providing the emerging market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services go to www.emergingstockreport.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.emergingstockreport.com/register.php
ESR Disclosure:
Emerging Stock Report is not a registered investment advisor and nothing in this release should be construed as a recommendation to buy or sell securities. Emerging Stock Report has not been compensated by the above mentioned companies.
CONTACT: Emerging Stock Report e-mail: info@emergingstockreport.com WWW: http://www.emergingstockreport.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index